Largest ever Parkinson’s research trial is starting now
Date
Research news
Date
Over the next 3 years, the US-based Parkinson’s Foundation will invest a minimum of $3m (over £2.4m) into the Parkinson’s Virtual Biotech, our international drug discovery and development programme.
Date
2 clinical trials aiming to reduce the clumps of troublesome alpha-synuclein to protect brain cells have, so far, failed to show a clear benefit for people with Parkinson’s.
Date
We are partnering with the British Neuroscience Association (BNA) to plan and deliver the BNA International Festival of Neuroscience 2023.
Date
Broadcasting legend and Parkinson's UK celebrity ambassador David ‘Kid’ Jensen is taking part in a world-first clinical trial. The trial will help researchers understand if an anti-sickness drug could treat hallucinations in people with Parkinson’s or Lewy body dementia.
Date
An important research partnership involving Parkinson’s UK, pharmaceutical company UCB and the Parkinson’s Foundation has published their first results in a study designed alongside people living with Parkinson’s.
Date
An app that links to Apple Watch technology has been granted FDA approval to help monitor some motor symptoms experienced by people with Parkinson’s.
Date
We’re calling on the Parkinson’s community to take part in 5 important clinical studies that are currently at risk of closure.
Date
Biotech company, NRG Therapeutics, has today announced an Innovate UK award to continue its drug development project, supported by the Parkinson's Virtual Biotech, into life-changing new treatments.
Date
Research led by Cambridge University and part funded by Parkinson’s UK shows that a form of brain scan could help identify those at risk of specific Parkinson’s symptoms.
Date
A trial of a new miniaturised deep brain stimulation (DBS) device, being carried out at Southmead Hospital in Bristol, aims to make improvements to existing surgery.